Liraglutide, a human GLP-1 analogue, significantly improves beta cell function in subjects with type 2 diabetes
Main Authors: | Matthews, DR, Marre, M, Le-Thi, T, Zdravkovic, M, Simo, R, Garber, A, Zinman, B |
---|---|
Format: | Journal article |
Published: |
2008
|
Similar Items
-
Liraglutide, a human GLP-1 analogue, reduces bodyweight in subjects with type 2 diabetes, irrespective of body mass index at baseline
by: Schmitz, O, et al.
Published: (2008) -
The reduction of body weight with liraglutide, a once-daily human GLP-I analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visceral fat
by: Jendle, J, et al.
Published: (2008) -
Liraglutide, a human GLP-1 analogue, lowers HbA(1c) independent of weight loss
by: Schmidt, W, et al.
Published: (2009) -
Liraglutide, a once-daily human GLP-1 analogue, in type 2 diabetes provides similar glycaemic control with reduced body weight compared with glimepiride when added to metformin
by: Hermansen, K, et al.
Published: (2008) -
The imaging of insulinomas using a radionuclide-labelled molecule of the GLP-1 analogue liraglutide: a new application of liraglutide.
by: Jing Lv, et al.
Published: (2014-01-01)